Vol.

No.

February 18, 2022Feb 18, 2022

DOWNLOAD THE PDF

White House’s Danielle Carnival: I’m moving the Cancer Moonshot forward with an all-of-government approach

Cover Story

Conversation with The Cancer Letter White House

White House’s Danielle Carnival: I’m moving the Cancer Moonshot forward with an all-of-government approach

By Matthew Bin Han Ong

Changes at Mission Control notwithstanding, the new Cancer Moonshot is ready for liftoff, says Danielle Carnival, coordinator of the White House cancer initiative.

NCI

NCI starts to unpack Biden’s Moonshot 2.0 goal to halve cancer death rates over 25 years

By Matthew Bin Han Ong

Conversation with The Cancer Letter COVID-19 & Cancer

AACR report: COVID-19 created barriers to cancer screening and care, but accelerated research and telemedicine

By Alice Tracey

Conversation with The Cancer Letter

The Mark Foundation plans to spend $500 million on cutting-edge cancer research

By Paul Goldberg

Black History Month Cancer History Project Conversation with The Cancer Letter Free

Edith Mitchell on her path from Tennessee farm to becoming a cancer doctor and brigadier general

By Robert A. Winn and John H. Stewart

Free In the Archives

Winn, Brawley, Mitchell, Stewart join the Cancer History Project for Black History Month panel

In Brief

Ben Ho Park named director of Vanderbilt-Ingram Cancer Center, succeeding Jennifer Pietenpol

Ross Levine named deputy physician-in-chief of translational research at Memorial Hospital

Robert Califf confirmed as FDA commissioner

Arul Chinnaiyan awarded Sjöberg Prize for prostate cancer research

Roy Herbst named inaugural deputy director for clinical affairs at Yale

Mark Lemmon, Daniel DiMaio, Megan King named to leadership roles at Yale

Candice Lucas named chief community impact officer at Wilmot Cancer Institute

ACS to establish breast cancer and cervical cancer roundtables

CPRIT issues over $112M in grants

Fox Chase receives R25 grant to expand undergraduate research opportunities

Reducing Hereditary Cancer Act introduced in Senate

Clinical Roundup

ACS National Consortium publishes recommendations to increase cancer screening rates to pre-pandemic levels

SWOG study: Women at higher risk of severe adverse events from targeted therapy, immunotherapy

Yale, Maryland study: IXA+BEV effective for patients with advanced ovarian cancer

Yale study validates enfortumab vedotin as therapy for aggressive bladder cancer

Interim findings from MIRAGE phase III randomized trial support MRIdian MRI guidance in SBRT for localized prostate cancer

Drugs & Targets

FDA grants Fast Track designation to IO-202, anti-LILRB4 myeloid checkpoint inhibitor for AML

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 06 - February 13, 2026